Our Pipeline: Highlighting the Promising Drugs in Development

GM28K - Treatment resistant depression (TRD):

A novel approach to treating Treatment-Resistant Depression (TRD), aiming to improve lives and reduce dependency. GM28K represents a groundbreaking advancement in addressing TRD, offering new hope for those struggling with this challenging condition.

GRE2811 - Treatment Of Alopecia

Targeting Alopecia with groundbreaking pharmaceutical therapy. GRE2811 stands at the forefront of our efforts to address hair loss, offering a new dimension in the treatment landscape for individuals grappling with Alopecia.

GM2813 - Gambling Disorder

Innovative solutions for combating Gambling Disorder. GM2813 represents a dedicated initiative to address the complexities of Gambling Disorder, offering a ray of hope for those entangled in the grip of compulsive gambling.

GM2814 - Mild Cognitive Impairment (MCI)

Addressing Mild Cognitive Impairment with advanced drug repurposing strategies. GM2814 symbolizes our commitment to enhancing cognitive health and function. By employing cutting-edge drug repurposing techniques,

Our Innovative Research Pipeline

Our innovative research pipeline underscores our dedication to pioneering pharmaceutical solutions that make a difference in the lives of individuals facing various challenges. Through these promising drug developments, we aim to contribute to a healthier, more resilient future.